Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Supernus Pharm (NQ: SUPN )

33.53 +0.57 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 614,085
Open 33.35
Bid (Size) 32.50 (1)
Ask (Size) 53.64 (2)
Prev. Close 32.96
Today's Range 33.02 - 33.71
52wk Range 25.80 - 42.09
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Supernus to Participate in the Jefferies Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets

Performance

YTD
-10.52%
-10.52%
1 Month
-8.66%
-8.66%
3 Month
-12.64%
-12.64%
6 Month
-5.84%
-5.84%
1 Year
+19.88%
+19.88%

More News

Read More
Supernus Announces First Quarter 2023 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Something Happened In Biotech Last Week
Via Talk Markets
Supernus Pharmaceuticals's Earnings: A Preview
Via Benzinga
FDA Rejects Supernus Pharma's Minimally Invasive Parkinson's Therapy
Via Benzinga
Earnings Scheduled For May 9, 2023
Via Benzinga
Supernus to Present at the Bank of America 2023 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Repayment of Convertible Notes
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Present at the Cowen 43rd Annual Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Enters Into $150 Million Credit Facility
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For February 28, 2023
Via Benzinga
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Via Talk Markets
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus to Present at Two November Healthcare Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Supernus Announces Third Quarter 2022 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Provides Regulatory Update on SPN-830
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Top Medical Specialties Stocks: Trading Opportunities For Next Week - Sunday, Oct. 2
Via Talk Markets
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.